<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="151165">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01664689</url>
  </required_header>
  <id_info>
    <org_study_id>OVD12</org_study_id>
    <nct_id>NCT01664689</nct_id>
  </id_info>
  <brief_title>Intraoperative and Postoperative Outcomes of Three Ophthalmic Viscosurgical Devices During Phacoemulsification</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Iladevi Cataract and IOL Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Iladevi Cataract and IOL Research Center</source>
  <oversight_info>
    <authority>India: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ophthalmic Viscosurgical Devices (OVDs) play a crucial role during phacoemulsification, by
      providing endothelial protection, maintaining space, as well as facilitating surgical
      maneuvers, including IOL implantation. Equally important is the ease of use, good
      visualisation and easy removal of the OVD from the eye. Currently, 3 popularly used OVDs as
      a single injection sufficing for surgery are: Healon 5, DiscoVisc, and Celoftal (2%
      hydroxypropylmethylcellulose). Whereas, there are studies showing efficacy of each of these
      in clinical scenarios, there is no randomized trial comparing intraoperative performance and
      postoperative outcomes. The aim of this study was to compare intraoperative performance and
      postoperative outcomes following microcoaxial phacoemulsification when using one of the
      three OVDs
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Corneal clarity on postoperative day 1</measure>
    <time_frame>postoperative day 1</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Central corneal thickness on postoperative day 1 and week 1</measure>
    <time_frame>day 1 and week 1</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Intraoperative Performance and Postoperative Outcomes Following Cataract Surgery</condition>
  <arm_group>
    <arm_group_label>DiscoVisc</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>microcoaxial phacoemulsification performed with discovisc</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healon 5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>microcoaxial phacoemulsification using healon 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Celoftal</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>microcoaxial phacoemulsification using celoftal</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Microcoaxial Phacoemulsification</intervention_name>
    <arm_group_label>DiscoVisc</arm_group_label>
    <arm_group_label>Healon 5</arm_group_label>
    <arm_group_label>Celoftal</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age related, uncomplicated senile cataracts

        Exclusion Criteria:

          -  presence of glaucoma,

          -  shallow anterior chamber (ACD &lt; 2.1mm),

          -  pupillary dilatation &lt; 6mm,

          -  extremely dense cataracts,

          -  posterior polar cataract,

          -  subluxated cataract,

          -  white mature cataract,

          -  diabetic retinopathy,

          -  high myopia (defined as AL &gt; 25mm),

          -  uveitis, or

          -  previous ocular trauma/surgery.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Iladevi Cataract &amp; IOL Research Centre</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380052</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <lastchanged_date>August 13, 2012</lastchanged_date>
  <firstreceived_date>August 10, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
